Nevertheless, superior antitumor activities were only achieved by combination treatment with durvalumab and oleclumab, which suggests that CD73 and PD-L1 jointly suppress T cells in the TME and that targeting of both CD73 and PD-L1 is required to induce optimal T cell response against EGFR-mutated NSCLC. This evidence concerns the gene NT5E and non-small cell lung carcinoma.